We aim to determine the differences in oral and intestinal microbial composition between community-dwelling older adults with and without malnutrition, further stratified to those with and without poor appetite.
ID
Source
Brief title
Condition
- Appetite and general nutritional disorders
Synonym
Research involving
Sponsors and support
Intervention
Outcome measures
Primary outcome
Main study parameter will be the intestinal microbial composition as determined
by 16S RNA-sequencing of frozen faecal samples.
Secondary outcome
We will investigate the oral microbiota as determined by 16S RNA-sequencing of
frozen, tongue swabs and salivary samples. We will further determine metabolic,
endocrine and inflammatory biomarkers from faecal, salivary and blood samples
to investigate the different pathways through which the microbiota influences
its host. We will also study the differences in oral microbiota and the
relationship with subjects* sense of taste and smell as these might also
influence loss of appetite.
Background summary
Seven to sixteen percent of the community-dwelling older adults is affected by
protein-energy malnutrition, posing several health and financial concerns.
Although various factors have been proposed to contribute to malnutrition in
the older adults, they have failed to lead to effective therapeutic and
preventative interventions. A new possible target may be the composition of
intestinal microbiota. Microbiota may influence nutritional status and appetite
through metabolic, endocrine and inflammatory pathways. We hypothesize that
microbial composition will differ significantly between malnourished and
well-nourished older adults with and without poor appetite. Determining these
differences will be detrimental in developing dietary-based pre- and probiotic
interventional measures.
Study objective
We aim to determine the differences in oral and intestinal microbial
composition between community-dwelling older adults with and without
malnutrition, further stratified to those with and without poor appetite.
Study design
A case-control study.
Study burden and risks
The current study will be performed in a relatively healthy population. It will
not contain an intervention and will not interfere with medical treatment. It
will target an important medical issue specific to this population and aims to
elucidate pathophysiological pathways responsible for malnutrition. Ultimately,
this study is being conducted in collaboration with the PROMISS research
consortium, that will use its results to develop new food products, which will
become commercially available and will be tailored to the nutritional needs and
preferences of the older adults. Therefore, the older adult population as a
whole would benefit from our study.
The subjects will be contacted by regular mail, phone and a single home-visit
and will not be required to travel. It will concern subjects that have already
agreed to participate in the LASA-cohort and are thus familiar with the concept
of scientific research. They will be required to fill out a questionnaire and
anthropometric and taste measurements will be done. Finally, oromucosal and
faecal samples will be obtained. Faecal sampling could be construed as a
burden, but does not pose any risks to the subjects* health. The procedure is
similar to the national screening program for colon carcinoma. Half of the
subjects will participate in further phenotyping consisting of smell tests and
salivary and blood sampling. From all study procedures, only blood sampling is
invasive. Sampling of peripheral venous blood will be performed once only by a
clinically experienced investigator. It carries the risk of hematoma (common,
low burden) and phlebitis (rare, low-intermediate burden).
Boelelaan 1117
Amsterdam 1081 HV
NL
Boelelaan 1117
Amsterdam 1081 HV
NL
Listed location countries
Age
Inclusion criteria
Age 65 years and older;
Mentally competent to agree with and participate in study;
Living at home (non-institutionalized);
Participant of the LASA-cohort (Longitudinal Aging Study Amsterdam).
Exclusion criteria
Body-Mass Index of 30 and above;
Active malignancy (with the exception of basal cell carcinoma);
History of inflammatory bowel disease;
Immune suppression (either medicinal or disease-related);
Use of antibiotics three months prior to faecal and salivary sampling;
Long-term admittance (more than 4 weeks) to hospital or long-term care facility in three months prior to faecal and salivary sampling;
Clinical symptoms of acute gastro-enteritis in the two weeks prior to faecal and salivary sampling (i.e. vomiting, acute diarrhoea).
Design
Recruitment
Followed up by the following (possibly more current) registration
No registrations found.
Other (possibly less up-to-date) registrations in this register
No registrations found.
In other registers
| Register | ID |
|---|---|
| CCMO | NL60911.029.17 |